CRISPR Therapeutics
CRSP
449 hedge funds and large institutions have $3.22B invested in CRISPR Therapeutics in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 159 increasing their positions, 128 reducing their positions, and 75 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 128
7% more call options, than puts
Call options by funds: $127M | Put options by funds: $119M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.09% less ownership
Funds ownership: 70.24% → 70.16% (-0.09%)
7% less funds holding
Funds holding: 484 → 449 (-35)
22% less capital invested
Capital invested by funds: $4.1B → $3.22B (-$881M)
35% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 75
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$52M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$33.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$30.7M |
| 4 |
BlackRock
New York
|
+$13.4M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$11.6M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$28.6M |
| 2 |
Morgan Stanley
New York
|
-$28.2M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$21.9M |
| 4 |
Barclays
London,
United Kingdom
|
-$11M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
CRSP Hedge Fund Activity: Q2 2024 in Review
449 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2024, worth a combined $3.22B — down 22% from $4.1B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of CRSP and 49 opened new positions — a net loss of 26 holders — while 128 trimmed existing stakes and 159 added.
The largest buyer was State Street, adding an estimated $52M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $28.6M sold.
- 449 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2024, down from 484 in Q1 2024.
- Funds reported $3.22B of CRISPR Therapeutics stock for Q2 2024, down 22% quarter-over-quarter.
- 49 funds opened new CRISPR Therapeutics positions in Q2 2024 and 75 closed out, a net change of -26 holders.
- The largest CRISPR Therapeutics buyer in Q2 2024 was State Street, an estimated $52M added.
- The largest CRISPR Therapeutics seller in Q2 2024 was Avoro Capital Advisors, an estimated $28.6M sold.
Based on aggregated 13F filings for Q2 2024.